Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / ANO1



This biomarker is also known as:
  • tumor-amplified and overexpressed sequence 2,
  • anoctamin-1,
  • Tumor-amplified and overexpressed sequence 2,
  • Oral cancer overexpressed protein 2,
  • transmembrane protein 16A,
  • ORAOV2,
  • TAOS2,
  • DOG1,
  • discovered on gastrointestinal stromal tumors protein 1,
  • oral cancer overexpressed 2,
  • transmembrane protein 16A (eight membrane-spanning domains),
  • Transmembrane protein 16A,
  • anoctamin 1, calcium activated chloride channel,
  • TMEM16A,
  • FLJ10261,
  • Discovered on gastrointestinal stromal tumors protein 1,

View in BioMuta


ANO1, or anoctamin-1, is a calcium-activated chloride channel gene overexpressed in many tumors. ANO1 is ubiquitously expressed in epithelia and is thought to be important in epithelial fluid transport.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


ANO1 is located within the 11q13 amplicon, one of the most frequently amplified chromosomal regions in human cancer. ANO1 is amplified and highly expressed in breast cancer cell lines and primary tumors.

Performance Comment

ANO1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.